GBAF Logo
Global Banking & Finance Awards® 2026 Nominations open, free to enter Nominate now →
J

JSP Pharmaceutical Manufacturing (Thailand) PCL JSP.BK · THB

N/A · SET · 🇹🇭 Thailand

Compare

1.68

+0.60%

Close of 9 Nov 2026, in THB

Search any instrument

Reference data, closing prices and charts across 45,000 companies, plus crypto, commodities and currencies.

About JSP Pharmaceutical Manufacturing (Thailand) PCL

Its shares trade on SET under the ticker JSP.BK. It has been listed since 2 November 2021. In the fiscal year to 31 December 2025, it reported revenue of THB 1.01bn and net income of THB 67.9m. At that date it held total assets of THB 1.46bn and shareholders' equity of THB 908.6m.

JSP Pharmaceutical Manufacturing (Thailand) Public Co. Ltd. operates the business of producing products according to customer needs, producing drugs, dietary supplements, cosmetics, herbs and dietary supplements in the form of vitamins to nourish the body. The company is headquartered in Bangkok, Bangkok Metropolis. The company went IPO on 2021-11-02. The firm manufactures and distributes products under customer’s brand name (OEM), as well as under the Company’s brand name. The firm develops, manufactures and sells conventional and traditional medicines, herbal products and dietary supplements, providing a range of services covering the manufacturer and the seller of the products under both customers’ trademark (OEM) and the seller of the products under the Company’s trademark (Own Brand). The firm develops herbal products, dietary supplements with natural extracts and plant-based protein under brand name Supap Osot, and dietary supplements such as using new raw materials or having new production process for both beauty and health under brand name EVITON. The Company’s subsidiary, Caresutic Co., Ltd., is engaged in manufacturing and distribution of dietary supplements and cosmetic products.

Figures and description from our data supplier, not checked against the company's own report.

Company facts

Sector
N/A
Industry
N/A
Listed since
2 Nov 2021
Employees
340

Leadership

Pay as last reported

  • Dr. Thongchai TawichachatIndependent Chairman of the Board
  • Dr. Sittichai DaengprasertPresident, Executive Director
  • Ms. Jirada DaengprasertExecutive Vice President - Finance and Accounting, Executive Director, Company Secretary
  • Mr. Pissanu DaengprasertExecutive Vice President - Business Development, Executive Director
  • Mr. Sorasit DaengprasertExecutive Vice President - Manufacturing, Executive Director
  • Mr. Tawat KitkangwanDirector
  • Ms. Jintana SantipisutDirector
  • Assoc. Prof. Dr. Lalita HongratanawongIndependent Director
  • Ms. Sophawadee LertmanatchaiIndependent Director
  • Mr. Vinit UsavakidvireeIndependent Director
  • Mr. Nuttawut WibulpattanawongIndependent Director

Environmental, social and governance

Scores out of 100, from our data supplier

ESG
Overall
0
Environment
0
Social
0
Governance
0

SWOT analysis

AI-generated by our data supplier. Not written or checked by our editors.

AI-generated

Strengths

  • Produces custom pharmaceuticals and dietary supplements under OEM and Own Brand models
  • Manufactures herbal products with natural extracts and plant-based protein under Supap Osot
  • Develops new dietary supplements using innovative raw materials and production processes for EVITON

Weaknesses

  • Limited to Bangkok headquarters for operations
  • Relies on customer brand name for OEM business model
  • Operates with only 340 employees in a growing market

Opportunities

  • Expanding into new markets beyond Thailand
  • Growing demand for herbal and natural health products globally
  • Increasing focus on plant-based protein supplements in the health sector

Threats

  • Competition from established pharmaceutical companies in Thailand
  • Regulatory changes affecting herbal product approvals
  • Economic downturns impacting consumer spending on supplements

Sources and methodology

Data on this tab
Our data supplier
Chart on the Overview
TradingView

Nothing here is investment advice. Prices can be delayed or wrong, so check with the exchange before relying on them. Data for this page. How we cover markets.